In this review article different relevant applications of botulinum toxin type A are demonstrated in patients with head and neck cancer.
Introduction
The clinical use of botulinum toxin type A (BTA) has increased during the last few years. A lot of movement disorders and disorders of the autonomous nerve system can be treated with this option. The head and neck region is one interdisciplinary focus in this field. Some indications are relevant for patients suffering from head and neck cancers (for a review see [1 ,2 ] ). BTA prevents the release of acetylcholine in synapses. Acetylcholine acts as a neurotransmitter for the innervation of muscles and different gland tissues. Blocking the release of acetylcholine leads to a reduction of pathological movement and secretion of glands in the head and neck area, thus increasing the quality of life for cancer patients.
Review
Pathological states as sequelae of cancer disease and/or cancer treatment include movement disorders of the facial nerve (facial-nerve palsy and synkinesis following defective healing of the facial nerve) and hyperactivity of the cricopharyngeal muscle, hypersalivation of different etiologies, hyperlacrimation and gustatory sweating.
Facial nerve paralysis, synkinesis following defective healing of the facial nerve BTA is helpful in certain movement disorders of the mimic musculature. In some cases a facial-nerve paralysis leads to an affection of the cornea, with severe problems like a keratitis e lagophthalmo [3] . In such cases an injection into the levator palpebrae muscle can close the eye for some time to protect the cornea (Fig. 1) . We use dosages of 5-10 units of Botox, injected subcutaneously in the middle of the upper lid. After about 3-4 months the eye 'opens' again, this period usually reflecting the regeneration time of the paralysis. In addition, the esthetic outcome of a paralysis of the marginal branch of the facial nerve can be improved by injecting 2.5-5 units of Botox into the depressor labii muscle of the normal side [3] .
Synkineses are unavoidable sequelae following reconstruction of the facial nerve in patients suffering from malignant tumors of the parotid gland (see Fig. 2 ). Synkineses are characterized by synchronous but unintended movements of certain areas of the mimic muscles, becoming mostly evident during spontaneous movements of the face based on emotional expressions. Mass movements can be reduced using BTA. This option was described first by our group (see [3] [4] [5] [6] ). Synkineses of the platysma are of special interest. We focused on this problem and found an acceptable decrease of complaints in treated patients [4] [5] [6] [7] .
We normally inject BTA using six injection points around the eye to reduce foreign movements of the orbicularis oculi muscle (see Fig. 3 ). The number and positions of injections and the total dosage depend on the extent of mass movements and may vary from patient to patient. We normally use dosages of 1.25-5 units of Botox at each injection point. Side effects are very rare, the reason for which could be that lower dosages are necessary to treat synkinesis compared to other facial dyskinesis, such as hemifacial spasm or blepharospasm.
Speech problems following laryngectomy
In some cases patients are not able to obtain an adequate level of speech for optimal communication. One reason for this is spasms of the cricopharyngeal muscle. In this situation BTA can reduce the muscular activity and improve speech quality [8] . We normally apply 3 Â 20 units of Botox, using three injection points. This procedure can be used as a test before planning myectomy or as a single therapeutic option that has to be repeated.
Hypersalivation
Hypersalivation is of high relevance for different reasons in patients suffering from head and neck cancers. Some patients of this group are not able to swallow their saliva because of a stenosis of the upper esophagus sphincter region caused by scar formation after a tumor resection. In other patients the sensory control of the entrance of the larynx is reduced and therefore saliva may pass the larynx and reach the trachea and the bronchus. This leads to permanent aspiration and aspiration pneumonia (Fig. 4) . In a third group of patients there may be problems of the wound-healing process after extended surgery, such as fistulas following laryngectomies. In these cases saliva is a very aggressive agent, preventing normal healing.
Based on our experiences [9, 10] , for our patients we prefer to use ultrasound-guided injection into the parotid and submandibular glands on each side. We inject into the parotid gland 22.5 units of Botox on each side, distributed between three points. The submandibular glands are treated by ultrasound-guided one-or two-point injection of a total of 15 units of Botox per gland. It has been shown by objective data in a lot of papers that BTA injections are effective in reducing saliva flow, accompanied by very few side effects.
Gustatory sweating
Gustatory sweating is a common sequela following parotid gland surgery, which includes cases of cancer of the 114 Head and neck oncology The dark color demonstrates the sweating area (left-hand panel). The sweating area is marked with a waterproof pen and subdivided in boxes (middle panel). Following intracutaneous injections of botulinum toxin type A the area is completely dry after gustatory stimulation (right-hand panel).
parotid gland [11] . In a lot of patients radiotherapy is not so relevant for treating parotid gland tumors and because of the extended resection of gland tissue the development of gustatory sweating is likely. The treatment of gustatory sweating with BTA was described first by our group in 1994 (the first patient was treated in December 1993; see [12] [13] [14] [15] ) and became the first-line treatment option in these patients.
To get an optimal outcome, we recommend marking of the sweating area by Minor's test and then dividing the sweating area into areas using a waterproof pen (see Fig. 5 ). The injections are done intracutaneously (see Fig. 5 ). The effectiveness of BTA treatment in patients with gustatory sweating has been confirmed by a lot of other authors (for example, see [16, 17 ] ). Some patients report a benefit after BTA injection on the same day and, interestingly, the positive effect remains much longer than in patients with movement disorders [14] . Some patients remain symptom-free for several years.
Hyperlacrimation
Hyperlacrimation can be caused by tumors of the maxilla, leading to a stenosis of the lacrimal duct (for example, see Fig. 6 ) by misdirected secretory fibers following a degenerative paresis of the facial nerve (crocodile tears) or after a mechanical irritation of the cornea (in patients with a lagophthalmus). The application of BTA is helpful to reduce pathological tear production in these patients [18] [19] [20] . We inject 5-7.5 units of Botox into the pars palpebralis of the lacrimal gland (for technique see the top right-hand panel of Fig. 6 ).
Conclusion
The application of BTA is helpful in several disorders that otherwise reduce the quality of life in patients with head and neck cancers of different etiologies.
The role of botulinum toxin Laskawi and Ellies 115 Figure 6 A patient suffering from myoepithelial carcinoma of the right maxillary sinus Top left: myoepithelial carcinoma of the right maxillary sinus. Lower left: after resection of the tumor the transport of tears into the nasal cavity was impossible so that the patient suffered from extensive hyperlacrimation. No surgical procedure had been successful. Following injection of botulinum toxin type A into the right lacrimal gland (see top right), hyperlacrimation was reduced but the eye did not become dry (lower right).
